We are live on ! Find out more
BLRX

BioLineRX

29 hedge funds and large institutions have $2.46M invested in BioLineRX in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

25% more capital invested

Capital invested by funds: $1.97M → $2.46M (+$490K)

12% more funds holding

Funds holding: 2629 (+3)

0% more ownership

Funds ownership: 0%0% (+0%)

11% less call options, than puts

Call options by funds: $635K | Put options by funds: $715K

Holders
29
Holders Change
+3
Holders Change %
+11.54%
% of All Funds
0.46%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
8
Reduced
6
Closed
5
Calls
$635K
Puts
$715K
Net Calls
-$80K
Net Calls Change
-$128K

BLRX Hedge Fund Activity: Q3 2023 in Review

29 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2023, worth a combined $2.46M — up 25% from $1.97M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BLRX positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 6 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $353K. The largest seller was Citadel Advisors, cutting an estimated $258K.

  • 29 institutional investors held BioLineRX (BLRX) as of Q3 2023, up from 26 in Q2 2023.
  • Funds reported $2.46M of BioLineRX stock for Q3 2023, up 25% quarter-over-quarter.
  • 8 funds opened new BioLineRX positions in Q3 2023 and 5 closed out, a net change of +3 holders.
  • The largest BioLineRX buyer in Q3 2023 was Sabby Management, an estimated $353K added.
  • The largest BioLineRX seller in Q3 2023 was Citadel Advisors, an estimated $258K sold.

Based on aggregated 13F filings for Q3 2023.